Millendo Therapeutics Stock

MLND

US60040X1037

Biotechnology & Medical Research

Latest news : Millendo Therapeutics

11/05/23	Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
30/12/22	Millendo Therapeutics, Inc. and Tempest Therapeutics, Inc. Enter into First Amendment to Loan and Security Agreement	CI
30/09/21	Millendo Therapeutics, Inc. Joins Nicholas Maestas as Vice President, Strategy and Finance and It's Principal Financial Officer	CI
25/06/21	Millendo Therapeutics, Inc.(NasdaqCM:MLND) dropped from NASDAQ Composite Index	CI
25/06/21	Tempest Therapeutics Inc. completed the acquisition of Millendo Therapeutics, Inc. in a reverse merger transaction for approximately $180 million.	CI
23/06/21	Millendo Therapeutics : , Tempest Therapeutics Investors Approve Merger Proposals	MT
13/05/21	Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	CI
29/03/21	Millendo Therapeutics, Inc., Tempest Therapeutics Inc. - M&A Call
29/03/21	Millendo Therapeutics : Tempest, Millendo Agree to Merge, Combined Company to List on NASDAQ	MT
29/03/21	Millendo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	CI
29/03/21	Tempest Therapeutics Inc. entered into a definitive agreement and plan of merger to acquire Millendo Therapeutics, Inc. in a reverse merger transaction.	CI
28/01/21	Millendo Therapeutics, Inc. Announces Executive Changes	CI
28/01/21	Millendo Therapeutics, Inc. Plans to Reduce Its Workforce with Majority of Reduction in Personnel Expects to Complete by April 15, 2021	CI

More news

Analysts' recommendations: Millendo Therapeutics

06/01/21	MILLENDO THERAPEUTICS : Ladenburg Thalmann Downgrades Millendo Therapeutics to Neutral from Buy	MT
06/01/21	MILLENDO THERAPEUTICS : SVB Leerink Downgrades Millendo Therapeutics to Market Perform From Outperform; Price Target is $2	MT
10/11/20	MILLENDO THERAPEUTICS : Wedbush Adjusts Price Target for Millendo Therapeutics to $2 From $3, Maintains Neutral Rating	MT

More recommendations

Press Releases: Millendo Therapeutics

24/07/21	TEMPEST THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
17/07/21	Tempest Therapeutics : BUSINESS (Form 8-K)	PU
17/07/21	TEMPEST THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
12/07/21	Tempest Therapeutics : to Participate in William Blair 2021 Biotech Focus Conference	AQ
12/07/21	TEMPEST THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ

More press releases

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MILLENDO THERAPEUTICS	-14.88%	+3.21%	-	-	303M
LONZA GROUP AG	+0.52%	-0.32%	-0.53%	+11.41%	47.74B
REVOLUTION MEDICINES, INC.	-1.73%	+0.32%	+393.48%	+615.17%	39.98B
BEONE MEDICINES AG	+0.62%	+2.35%	+10.75%	+44.88%	36.23B
IQVIA HOLDINGS INC.	+13.03%	+19.19%	+21.51%	+6.26%	35.59B
CELLTRION, INC.	-0.73%	+2.78%	+4.65%	+41.16%	27.91B
ASCENDIS PHARMA A/S	-1.38%	-2.36%	-	-	16.71B
MEDPACE HOLDINGS, INC.	-0.64%	+10.07%	+29.17%	+129.67%	16.45B
EUROFINS SCIENTIFIC SE	+2.30%	-1.72%	+4.65%	+9.85%	13.21B
ICON PUBLIC LIMITED COMPANY	+7.19%	+8.41%	-4.76%	-28.36%	12.93B
Average	+0.44%	+2.78%	+57.36%	+103.75%	27.42B
Weighted average by Cap.	+2.07%	+2.95%	+75.95%	+130.56%

See all sector performances

Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.

Employees

Sector

Biotechnology & Medical Research

More about the company